BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
FAST NEWS: InnoCare’s loss narrows on higher lymphoma drug sales
The latest: InnoCare Pharma Ltd. (9969.HK) announced on Monday its third quarter revenue dropped 18.3% year-over-year to 160 million yuan ($21.9 million), while its net loss narrowed 72.2% to 109 million yuan.…
FAST NEWS: InnoCare inches closer to profitability on strong sales gains
The latest: InnoCare Pharma Ltd. (9969.HK) announced Tuesday its first-quarter revenue jumped 59% year-over-year to 189 million yuan ($27.3 million), while its net loss narrowed 90% to 12.41 million yuan. Looking…
FAST NEWS: InnoCare Pharma’s Loss Soars on R&D Costs, Exchange Losses
The latest: InnoCare Pharma Ltd. (9969.HK) said it expects to report its net loss soared about 13 times to 910 million yuan ($134 million) last year, according to a profit…
InnoCare Revs Up for Next Phase With Strong Results, IPO Plan
Sales of the company’s key Orelabrutinib cancer drug doubled in the first half of the year, contributing to a 142% revenue jump for the period Key Takeaways: InnoCare Pharma’s revenue…
FAST NEWS: InnoCare Pharma Losses Double on Higher Costs And Exchange Deficit
The latest: InnoCare Pharma Ltd. (9969.HK) issued a profit warning Friday, estimating a net loss of no more than 495 million yuan ($73 million) for the first half of this year,…
FAST NEWS: InnoCare Pharma Granted Production Approval for Guangzhou Facility
The latest: InnoCare Pharma Ltd. (9969.HK) announced Monday its Guangzhou manufacturing facility has been approved by the China National Medical Products Administration (NMPA) to start the production of commercial supply of its…
Recent Articles
RELATED ARTICLES
-
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
9969.HK 688428.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
DPC Dash serves up banner 2024 topped with milestones
1405.HK
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Dingdong rings up strong end to 2024, but warns of turbulence ahead
DDL.US
-
After profit plunge in 2024, Maoyan spotlights strong start to 2025
1896.HK
